Investigating nephroprotective measures for critically ill patients with acute kidney injury
Implementation of Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury (AKI) - an Observational Study
This study looks at how well hospitals follow guidelines to protect the kidneys of critically ill patients with moderate to severe acute kidney injury to see if it can help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 257 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universität Münster Academic / other |
| Locations | 3 sites (Innsbruck and 2 other locations) |
| Trial ID | NCT06472999 on ClinicalTrials.gov |
What this trial studies
This observational study examines the implementation of recommended nephroprotective measures in critically ill patients suffering from moderate to severe acute kidney injury (AKI). AKI is a significant global health issue, particularly in hospitalized patients, and can lead to chronic kidney disease if not managed properly. The study focuses on the adherence to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which propose a bundle of supportive measures aimed at preventing the progression of kidney injury. By assessing current practices, the study aims to identify gaps in care and improve outcomes for patients with AKI.
Who should consider this trial
Good fit: Ideal candidates for this study are critically ill patients aged 18 and older with moderate or severe acute kidney injury requiring vasopressors or mechanical ventilation.
Not a fit: Patients with chronic kidney disease, those on chronic dialysis, or individuals with a history of renal transplantation are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of acute kidney injury, potentially improving survival rates and reducing the risk of chronic kidney disease.
How similar studies have performed: Previous studies have indicated that adherence to KDIGO guidelines can improve outcomes in patients with acute kidney injury, suggesting that this approach has shown promise.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Critically ill patients with moderate or severe AKI (KDIGO stage 2 / 3) 2. Requirement of vasopressors or mechanical ventilation 3. Age ≥ 18 years 4. Informed consent Exclusion Criteria: 1. Chronic kidney disease (CKD) with a glomerular filtration rate \< 20ml/min 2. Chronic dialysis dependency 3. History of renal transplantation 4. Permanent ligation of the renal arteries 5. AKI immediately following nephrectomy 6. Patients requiring permanent administration of nephrotoxic drugs (e.g. immunosuppressive therapy afer liver transplantation) 7. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator.
Where this trial is running
Innsbruck and 2 other locations
- Universitätsklinik Innsbruck — Innsbruck, Austria (Recruiting)
- University Hospital Münster; Department of Anesthesiology, Intensive Care Medicine and Pain Medicine — Münster, Germany (Recruiting)
- Radboud University medical cener — Nijmegen, Netherlands (Recruiting)
Study contacts
- Principal investigator: Alexander Zarbock, MD — University Münster
- Study coordinator: Melanie Meersch-Dini, MD
- Email: meersch@uni-muenster.de
- Phone: +492518347255
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.